Moody's Ratings (Moody's) has completed a periodic review of the ratings of Lanxess AG and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 15 November 2024 in which we reassessed the appropriateness of the ratings in the context of the...
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and , a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate shigellosis vacc...
Valneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en Europe Saint-Herblain (France), le 12 novembre 2024 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et participeront à des rendez-vous avec des investisseurs institutionnels lors de prochaines conférences aux États-Unis et en Europe. Lors de ces présentations, Thomas Lingelbach, directeur général, et Peter Bühler, directeur financier, feront un point sur les principaux é...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences Saint-Herblain (France), November 12, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming cataly...
>Q3 2024 sales came to € 7.8m, up 13% yoy, close to our estimate - Yesterday after the close Wallix reported Q3 2024 revenue of € 7.8m, up 13.4% yoy, just below our estimate of € 8.0m. While this means that growth accelerated qoq (Q2 +4.6%), the increase appears a bit weak vs the group’s guidance. As a reminder, reported growth continues to be temporarily penalised by the ongoing business model transition (to SaaS) with monthly recurring revenue (MRR) at end-September...
>CA T3 2024 de 7.8 M€, en croissance de 13% y/y, proche de nos attentes - Wallix a publié hier après Bourse un CA T3 2024 de 7.8 M€, en hausse de 13.4% y/y, marginalement inférieur à notre estimation initiale (ODDO BHF 8.0 M€). Si cela traduit une accélération de la croissance en séquentiel (T2 +4.6%), cette hausse apparait encore un peu ‘soft’ par rapport aux ambitions du groupe. Pour rappel, la croissance affichée est toujours temporairement pénalisée par la transit...
>Q3 EBITDA pre of €173m 2% ahead of cons (€ 169m) with volume recovery across all BUs, except Ag (Saltigo) - Group sales were flat y-o-y at €1,598m (cons €1,658m) including 5% y-o-y higher volumes (Q2 2024: 0% y-o-y) where Lanxess flagged 9 out of 10 BUs with higher volumes, except Saltigo (Ag) weighing on -5% y-o-y reported in Consumer Protection volumes. Price erosion was -4% y-o-y (Q2 24: -6%) mainly on pass through of lower raw materials prices. EBITDA pre of €17...
>Top line in line and EBITDA higher than expected – Disappointment on Ixchiq - Valneva reported 9M 2024 results in line with expectation for sales (+0%) and above the css for adjusted EBITDA (+13%). Product sales rose 6% to € 110.4m (+2% vs css) driven by Ixiaro (+31%, +4% vs css) and Dukoral (+6%, +10% vs css) boosted in Q3 (+85%) by the pick-up in marketing outlays. The disappointment in this release came from the performance of Ixchiq which is struggling to get goi...
>Topline en ligne et EBITDA au-dessus des attentes – Déception sur Ixchiq - Valneva publie des résultats 9M 2024 en ligne au niveau du CA (+0%) et au-dessus du css au niveau de l’EBITDA ajusté (+13%). Les ventes de produits sont en hausse de 6% à 110.4 M€ (+2% vs Css) tirées par Ixiaro (+31%, +4% vs css) et Dukoral (+6%, +10% vs css) bénéficiant au T3 (+85%) de la reprise des investissements en marketing. La déception de cette publication provient de la performance d’...
Valneva has reported a mixed-bag of 9M results with sales at EUR112.5m (cons. EUR110.4m) +12% yoy (excluding Covid-19 revenue in 2023), operating profit of EUR34.2m (cons. EUR29m), translating into an underlying est. EUR61m operating loss excluding the EUR95m profit from the sale of the Priority Vo
TomTom and CARIAD bring next-gen navigation to the road Starting with premium electric vehicles from Audi, the new solution will gradually come to power Volkswagen Group’s vehicle line-up AMSTERDAM, Nov. 07, 2024 (GLOBE NEWSWIRE) -- TomTom (), the location technology specialist, today announced that the first models from Volkswagen Group brands featuring TomTom and CARIAD’s co-developed next-generation navigation solution are taking to the roads. Starting with premium electric vehicles (EV) from Audi, the new navigation solution is tightly integrated into the vehicle platform, providing...
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to the agreed R&D b...
Valneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2024 et fait un point sur ses activités Principaux éléments financiers pour les neuf premiers mois de l’exercice 2024 Chiffre d’affaires total de 116,6 millions d’euros comprenant des ventes de produits de 112,5 millions d’eurosBénéfice net de 24,7 millions d’euros incluant le produit de la vente du bon de revue prioritaire (PRV)1 Bénéfice opérationnel de 34,2 millions d’euros contre une perte opérationnelle de (57,2) millions d’euros sur les neuf premiers mois de l’exercice 2023 Trésorerie de 156,3 millions ...
Notre scénario central s’est concrétisé dans la nuit : Donald Trump remporte la présidentielle américaine, et le choix des électeurs ne devrait pas être contesté. Il pourrait disposer d’une majorité dans les deux assemblées. Les actions américaines en seront les premières bénéficiaires. Sur les actions européennes, les secteurs les plus gagnants seront l’Energie, les Médias, les Métaux, Construction & Materials, Financial Services, Insurance. Sont en revanche plus à risque Utilities, ...
Our baseline scenario materialised last night: Donald Trump seems to be on course to win the US presidential election, and the choice of the electorate is unlikely to be challenged. He could end up with a majority in both houses of Congress. US equities will be the first to benefit from this development. In European equities, the biggest winners will be Energy, Media, Metals, Construction & Materials, Financial Services and Insurance. More at risk, however, are the Utilities, Spirits,...
VALNEVA - Declaration of shares and voting rights: October 31, 2024 VALNEVA Declaration of shares and voting rights October 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: November 6, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal num...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.